EL DORADO HILLS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- NutraStar(TM) Incorporated (OTC Bulletin Board: NTRA) (Berlin: NTQ) announced today that a double-blind cross-over study, which was published in the March 2002 issue of the Journal of Nutritional Biochemistry and resulted in the issuance of U.S. Patent No. 6,126,943 may hold a key for millions of people who are fighting diabetes I and II by helping to control blood glucose levels.
"The data from this clinical trial indicates that supplementing the diet with products derived from specially processed stabilized rice bran derivatives may help lower blood sugar levels in both Type I and Type II diabetics by as much as 30%," said Dr. Barbara Levine, Director of the Human Nutrition Program at Cornell Medical College and Rockefeller University.
"This is a significant finding in view of the short duration of the study," said Dr. Asaf Qureshi, chief investigator of the study. "One out of four diabetics in the 57-subject study lowered their daily dosage of medication by 30%-60% just by adding these special stabilized rice bran derivatives, RiSolubles(R) and RiceMucil(R), to their daily diet. While not all of the subjects were able to reduce their hyperglycemic medications, all of the subjects were able to maintain a lower blood glucose level on these regimens as compared to their respective placebo groups."
Dr. Qureshi and his colleagues at Advanced Medical Research in Madison, Wisconsin found that by consuming 20 grams per day of either RiSolubles(R) or RiceMucil(R) for 60 days, both Type I and Type II diabetics were able to lower their blood sugar levels by 30% and 20%, respectively.
"In addition, the study also found that the stabilized rice bran derivatives were able to lower total serum cholesterol and total triglyceride levels between 5% and 15% in subject with marginally elevated cholesterol. "Not only was there a decrease in blood glucose levels," said Levine, "but there was also a lowering of the serum lipid parameters in these diabetic patients."
NutraStar(TM) is the exclusive world-wide licensee of the rights to U.S. Patent Number 6,126,943, issued on October 16, 2001. The patent is held by The RiceX Company (OTC Bulletin Board: RICX), the exclusive manufacturer of the stabilized rice bran derivatives, which were used in the study. RiceX and NutraStar jointly prosecuted the patent entitled "A Method for Treating Hyperglycemia, Hypoglycemia and Diabetes."
NutraStar(TM) Incorporated is emerging as a pioneering, science-based growth company. NutraStar is focused on becoming the world's leading nutraceutical company through the development and distribution of its proprietary stabilized rice bran "super foods", natural arthritic relief products for humans and animals and "all natural" cosmeceuticals and beauty aids. The company is headquartered at 1261 Hawk's Flight Court, El Dorado Hills, California 95762.
Interested persons are encouraged to visit the company's website at www.nutrastar.com
This release contains statements that are forward looking. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.